A Study of Lebrikizumab (LY3650150) Administered by Two Different Devices in Healthy Participants

Exclusion Criteria

• •Are females who are pregnant or lactating.
• •Have a history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs
• •Have a history or presence of psychiatric disorders
• •Show evidence of human immunodeficiency virus infection.
• •Show evidence of hepatitis C and/or hepatitis B
• •Medical history of allergic reaction to humanized monoclonal antibodies
• •Have had lymphoma, leukemia, or any malignancy within the past 5 years except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of metastatic disease for 3 years.
• •Are currently enrolled in any other clinical study involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study.
• •Smoke more than 10 cigarettes per day or the equivalent including electronic cigarettes or are unable to abide by CRU smoking restrictions